Med Business World

Your source for healthcare business

Sigrun Pedersen

DRAWBRIDGE SECURES FDA 510(K) CLEARANCE FOR AT-HOME BLOOD SAMPLING DEVICE NANODROP

Drawbridge Health, a healthcare technology company focused on reinventing the blood draw experience, today announced that its at-home, patented blood sampling device, NanoDrop, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Over-the-Counter use. The clearance of this…

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere.  During a…

SweetWater Brewing Launches Hammer Red Amber Ale to Support Georgia Aquarium

 SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest craft brewer in the Southeast and a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), announced today the release of its new Hammer Red Amber Ale, the latest collaboration beer as…

SmartAlpha Partners with Siemens Healthineers to advance AI-powered Workflow Efficiencies in Ultrasound

SmartAlpha has announced a partnership with Siemens Healthineers with a signing ceremony at the European Congress of Radiology (ECR). This partnership signifies a milestone, by both companies, to provide innovative AI-powered applications that improve workflow efficiencies with consistency to optimize clinical…

Groundbreaking New Blood Test Offers Early Pancreatic Cancer Diagnosis Study Says

As reported in today’s issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism and that these changes can be measured with…

Reese Pharmaceutical Launches New At-Home Colon Cancer Screening Test

Reese Pharmaceutical is expanding its over-the-counter (OTC) diagnostic portfolio with the launch of ColoTest®, an at-home Fecal Immunochemical Test (FIT) that identifies the presence of hidden blood in the stool in support of the early detection of colon cancer or gastrointestinal disorders…

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Zealand Pharma A/S (Nasdaq: ZEAL) today announced that Boehringer Ingelheim has reported that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase 2…

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab)…

Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it has received clearance from the US Food and Drug Administration (FDA) to initiate a global…

Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001 

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical stage company, announced that it has dosed the first patient with Rheumatoid Arthritis (RA) in a Phase Ⅲ clinical trial of its highly selective JAK1 inhibitor LNK01001….